Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 30 studies | 33% ± 15% | |
macrophage | 22 studies | 32% ± 16% | |
fibroblast | 17 studies | 27% ± 10% | |
astrocyte | 17 studies | 42% ± 18% | |
oligodendrocyte | 15 studies | 46% ± 16% | |
oligodendrocyte precursor cell | 14 studies | 41% ± 18% | |
pericyte | 13 studies | 28% ± 13% | |
glutamatergic neuron | 12 studies | 53% ± 24% | |
microglial cell | 12 studies | 43% ± 11% | |
classical monocyte | 11 studies | 25% ± 7% | |
GABAergic neuron | 11 studies | 50% ± 23% | |
endothelial cell of lymphatic vessel | 10 studies | 30% ± 14% | |
epithelial cell | 10 studies | 37% ± 20% | |
myeloid cell | 10 studies | 33% ± 14% | |
non-classical monocyte | 9 studies | 24% ± 8% | |
adipocyte | 9 studies | 41% ± 9% | |
smooth muscle cell | 9 studies | 27% ± 9% | |
type I pneumocyte | 8 studies | 25% ± 10% | |
capillary endothelial cell | 8 studies | 20% ± 7% | |
neuron | 8 studies | 45% ± 17% | |
monocyte | 8 studies | 34% ± 11% | |
T cell | 8 studies | 24% ± 10% | |
retinal ganglion cell | 7 studies | 34% ± 11% | |
basal cell | 7 studies | 30% ± 18% | |
ciliated cell | 7 studies | 27% ± 9% | |
retinal cone cell | 7 studies | 26% ± 7% | |
natural killer cell | 6 studies | 21% ± 5% | |
interneuron | 6 studies | 56% ± 22% | |
club cell | 6 studies | 28% ± 6% | |
amacrine cell | 6 studies | 26% ± 8% | |
retina horizontal cell | 6 studies | 26% ± 7% | |
dendritic cell | 6 studies | 33% ± 4% | |
endothelial cell of artery | 6 studies | 18% ± 2% | |
type II pneumocyte | 6 studies | 23% ± 7% | |
abnormal cell | 5 studies | 26% ± 13% | |
B cell | 5 studies | 25% ± 6% | |
cardiac muscle cell | 5 studies | 28% ± 7% | |
lymphocyte | 5 studies | 32% ± 11% | |
respiratory goblet cell | 5 studies | 30% ± 8% | |
granule cell | 4 studies | 40% ± 12% | |
retinal pigment epithelial cell | 4 studies | 34% ± 21% | |
CD8-positive, alpha-beta T cell | 4 studies | 21% ± 3% | |
retinal rod cell | 4 studies | 25% ± 5% | |
endothelial cell of vascular tree | 4 studies | 29% ± 16% | |
mast cell | 4 studies | 27% ± 8% | |
myofibroblast cell | 4 studies | 27% ± 15% | |
alveolar macrophage | 4 studies | 40% ± 18% | |
ionocyte | 3 studies | 34% ± 10% | |
conventional dendritic cell | 3 studies | 25% ± 11% | |
hematopoietic precursor cell | 3 studies | 27% ± 9% | |
glomerular endothelial cell | 3 studies | 23% ± 3% | |
GABAergic interneuron | 3 studies | 49% ± 2% | |
glial cell | 3 studies | 32% ± 5% | |
progenitor cell | 3 studies | 30% ± 4% | |
squamous epithelial cell | 3 studies | 37% ± 22% | |
brush cell | 3 studies | 30% ± 6% | |
retinal bipolar neuron | 3 studies | 22% ± 5% | |
CD4-positive, alpha-beta T cell | 3 studies | 22% ± 1% | |
mesothelial cell | 3 studies | 25% ± 6% | |
mononuclear phagocyte | 3 studies | 31% ± 9% | |
vein endothelial cell | 3 studies | 33% ± 15% | |
GABAergic amacrine cell | 3 studies | 31% ± 9% | |
Mueller cell | 3 studies | 32% ± 3% | |
OFF-bipolar cell | 3 studies | 24% ± 5% | |
ON-bipolar cell | 3 studies | 25% ± 5% | |
glycinergic amacrine cell | 3 studies | 27% ± 3% | |
rod bipolar cell | 3 studies | 25% ± 7% | |
hepatocyte | 3 studies | 38% ± 17% | |
connective tissue cell | 3 studies | 27% ± 8% | |
ependymal cell | 3 studies | 50% ± 16% | |
CD16-positive, CD56-dim natural killer cell, human | 3 studies | 20% ± 4% | |
Schwann cell | 3 studies | 30% ± 17% | |
muscle cell | 3 studies | 31% ± 20% | |
goblet cell | 3 studies | 36% ± 22% | |
mural cell | 3 studies | 41% ± 10% | |
mucus secreting cell | 3 studies | 26% ± 7% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 5384.95 | 1445 / 1445 | 100% | 28.00 | 183 / 183 |
brain | 100% | 5647.30 | 2640 / 2642 | 100% | 36.85 | 704 / 705 |
lung | 100% | 6276.78 | 578 / 578 | 100% | 18.92 | 1152 / 1155 |
breast | 100% | 6465.53 | 459 / 459 | 99% | 28.66 | 1105 / 1118 |
bladder | 100% | 5776.24 | 21 / 21 | 97% | 16.51 | 491 / 504 |
thymus | 100% | 5502.04 | 653 / 653 | 97% | 17.47 | 589 / 605 |
kidney | 100% | 3186.48 | 89 / 89 | 97% | 17.23 | 875 / 901 |
intestine | 100% | 5290.27 | 966 / 966 | 96% | 13.58 | 507 / 527 |
uterus | 100% | 5987.97 | 170 / 170 | 96% | 14.58 | 441 / 459 |
stomach | 100% | 3404.70 | 359 / 359 | 96% | 17.16 | 274 / 286 |
prostate | 100% | 4382.40 | 245 / 245 | 95% | 16.20 | 479 / 502 |
pancreas | 97% | 1981.21 | 317 / 328 | 98% | 15.85 | 175 / 178 |
adrenal gland | 100% | 4115.40 | 258 / 258 | 93% | 12.42 | 215 / 230 |
ovary | 100% | 4516.26 | 180 / 180 | 93% | 9.19 | 401 / 430 |
skin | 100% | 6887.49 | 1809 / 1809 | 93% | 18.43 | 437 / 472 |
liver | 100% | 1880.81 | 225 / 226 | 73% | 6.62 | 298 / 406 |
adipose | 100% | 7314.39 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 6470.73 | 1335 / 1335 | 0% | 0 | 0 / 0 |
muscle | 100% | 4055.43 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 4102.92 | 241 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 7.00 | 1 / 1 |
heart | 98% | 3910.27 | 845 / 861 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 96% | 15.46 | 43 / 45 |
peripheral blood | 85% | 2619.44 | 789 / 929 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 83% | 10.38 | 66 / 80 |
lymph node | 0% | 0 | 0 / 0 | 76% | 8.63 | 22 / 29 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_1901985 | Biological process | positive regulation of protein acetylation |
GO_0006281 | Biological process | DNA repair |
GO_0032874 | Biological process | positive regulation of stress-activated MAPK cascade |
GO_0051493 | Biological process | regulation of cytoskeleton organization |
GO_0046330 | Biological process | positive regulation of JNK cascade |
GO_0006974 | Biological process | DNA damage response |
GO_0007026 | Biological process | negative regulation of microtubule depolymerization |
GO_0007095 | Biological process | mitotic G2 DNA damage checkpoint signaling |
GO_0070050 | Biological process | neuron cellular homeostasis |
GO_0021954 | Biological process | central nervous system neuron development |
GO_0000226 | Biological process | microtubule cytoskeleton organization |
GO_0097194 | Biological process | execution phase of apoptosis |
GO_0016310 | Biological process | phosphorylation |
GO_0070507 | Biological process | regulation of microtubule cytoskeleton organization |
GO_0006468 | Biological process | protein phosphorylation |
GO_0046777 | Biological process | protein autophosphorylation |
GO_0032956 | Biological process | regulation of actin cytoskeleton organization |
GO_0048471 | Cellular component | perinuclear region of cytoplasm |
GO_0070062 | Cellular component | extracellular exosome |
GO_0005829 | Cellular component | cytosol |
GO_0015630 | Cellular component | microtubule cytoskeleton |
GO_0005737 | Cellular component | cytoplasm |
GO_0048487 | Molecular function | beta-tubulin binding |
GO_0106310 | Molecular function | protein serine kinase activity |
GO_0016740 | Molecular function | transferase activity |
GO_0004674 | Molecular function | protein serine/threonine kinase activity |
GO_0004672 | Molecular function | protein kinase activity |
GO_0043539 | Molecular function | protein serine/threonine kinase activator activity |
GO_0050321 | Molecular function | tau-protein kinase activity |
GO_0043014 | Molecular function | alpha-tubulin binding |
GO_0005524 | Molecular function | ATP binding |
GO_0016301 | Molecular function | kinase activity |
GO_0048156 | Molecular function | tau protein binding |
GO_0005515 | Molecular function | protein binding |
Gene name | TAOK1 |
Protein name | non-specific serine/threonine protein kinase (EC 2.7.11.1) Serine/threonine-protein kinase TAO1 (EC 2.7.11.1) (Kinase from chicken homolog B) (hKFC-B) (MARK Kinase) (MARKK) (Prostate-derived sterile 20-like kinase 2) (PSK-2) (PSK2) (Prostate-derived STE20-like kinase 2) (Thousand and one amino acid protein kinase 1) (TAOK1) (hTAOK1) |
Synonyms | MAP3K16 MARKK KIAA1361 |
Description | FUNCTION: Serine/threonine-protein kinase involved in various processes such as p38/MAPK14 stress-activated MAPK cascade, DNA damage response and regulation of cytoskeleton stability. Phosphorylates MAP2K3, MAP2K6 and MARK2. Acts as an activator of the p38/MAPK14 stress-activated MAPK cascade by mediating phosphorylation and subsequent activation of the upstream MAP2K3 and MAP2K6 kinases. Involved in G-protein coupled receptor signaling to p38/MAPK14. In response to DNA damage, involved in the G2/M transition DNA damage checkpoint by activating the p38/MAPK14 stress-activated MAPK cascade, probably by mediating phosphorylation of MAP2K3 and MAP2K6. Acts as a regulator of cytoskeleton stability by phosphorylating 'Thr-208' of MARK2, leading to activate MARK2 kinase activity and subsequent phosphorylation and detachment of MAPT/TAU from microtubules. Also acts as a regulator of apoptosis: regulates apoptotic morphological changes, including cell contraction, membrane blebbing and apoptotic bodies formation via activation of the MAPK8/JNK cascade. Plays an essential role in the regulation of neuronal development in the central nervous system . Also plays a role in the regulation of neuronal migration to the cortical plate (By similarity). . |
Accessions | A0A994J797 ENST00000583121.5 ENST00000536202.1 [Q7L7X3-3] ENST00000578653.1 Q7L7X3 ENST00000261716.8 [Q7L7X3-1] J3QS76 |